| Company: | Boston Scientific Corporation |
|---|---|
| CEO: |
|
| Founded: | 1979 |
| Symbol: | BSX |
| Exchange: | NYSE |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| About |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products,luding drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company wasorporated in 1979 and is headquartered in Marlborough, Massachusetts. |
27 among 2804 companies
300 Boston Scientific Way
Marlborough | MA |
US
| Boston Scientific Corporation;BSX;http://bullfincher.io/logos/us/BSX.png;boston-scientific-corporation | 20074000000.00 |
|---|---|
| Stryker Corporation;SYK;http://bullfincher.io/logos/us/SYK.png;stryker-corporation | 25116000000.00 |
| Abbott Laboratories;ABT;http://bullfincher.io/logos/us/ABT.png;abbott-laboratories | 44328000000.00 |
| DexCom;DXCM;http://bullfincher.io/logos/us/DXCM.png;dexcom | 4662000000.00 |
Boston Scientific Corporation was founded on 1979, which makes the company 47 years old.
Michael F. Mahoney is the CEO of Boston Scientific Corporation.
Boston Scientific Corporation operates in the Medical - Devices industry and the Healthcare sector.
Boston Scientific Corporation has 59,000 employees.
In fiscal year 2025, Boston Scientific Corporation generated a revenue of $20.07 Billion.
In fiscal year 2025, Boston Scientific Corporation reported a net income of $2.89 Billion.
Cardiovascular is Boston Scientific Corporation's biggest product segment, representing 66.02% of its total revenue.
Boston Scientific Corporation went public on May 19, 1992, through its Initial Public Offering (IPO), and it has been 34 years since then.
Boston Scientific Corporation's ticker symbol is BSX, and the company is listed on the NYSE stock market exchange.
Boston Scientific Corporation's current stock price is $48.33 as of May 30, 2026.
Ranked #27among 2,804 companies based on market cap.
Competitors of Boston Scientific Corporation include Stryker Corporation, Abbott Laboratories and DexCom, and more.